0.93
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
What drives Prelude Therapeutics Incorporated stock priceUnmatched profit growth - PrintWeekIndia
Is Prelude Therapeutics Incorporated a good long term investmentSkyrocketing investment returns - PrintWeekIndia
What analysts say about Prelude Therapeutics Incorporated stockRapid wealth accumulation - Autocar Professional
Will Prelude Therapeutics Incorporated stock split in the near futureExplosive trading opportunities - jammulinksnews.com
Prelude Therapeutics Advances Cancer Treatment with PRT7732 Study - TipRanks
Prelude Therapeutics Incorporated Stock Analysis and ForecastExplosive capital gains - jammulinksnews.com
what makes prelude therapeutics incorporated stock price move sharplyFree Investment Community - Newser
Is Prelude Therapeutics Incorporated stock a good hedge against inflation10x Return With Managed Risk - Newser
What makes Prelude Therapeutics Incorporated stock price move sharplyFree Access to Investment Community - Newser
Why Prelude Therapeutics Incorporated stock attracts strong analyst attentionPro Trader Stock Focus - Newser
How Prelude Therapeutics Incorporated stock performs during market volatilityFree Smart Investment Opportunities - Newser
Prelude Therapeutics’ PRT7732 Study: A Potential Game-Changer for SMARCA4 Mutations - TipRanks
Prelude Therapeutics Advances PRT3789 in Phase 1 Study for SMARCA4 Mutant Tumors - TipRanks
Prelude Therapeutics Advances Cancer Treatment with New Phase 2 Study - TipRanks
Transcript : Prelude Therapeutics Incorporated Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 09 - MarketScreener
Baker Bros. Advisors LP Increases Stake in Prelude Therapeutics Inc. - GuruFocus
Two Sigma Investments LP Purchases 174,906 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Acquired by Millennium Management LLC - Defense World
20,572 Shares in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Purchased by BNP Paribas Financial Markets - Defense World
Two Sigma Advisers LP Raises Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Phio Pharmaceuticals Advances 30-Drug Cancer Portfolio as Phase 1b Trial Shows Promise - Stock Titan
Prelude Therapeutics describes new SMARCA2 and SMARCA4 degradation inducers - BioWorld MedTech
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Sold by Northern Trust Corp - Defense World
Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025 - MyChesCo
Prelude Therapeutics to Participate in Upcoming Healthcare Confe - GuruFocus
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences | PRLD Stock News - GuruFocus
Precision Oncology Pioneer Prelude Therapeutics Sets Stage for Major June Healthcare Conference Updates - Stock Titan
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):